Levamisole Hydrochloride is a synthetic imidazothiazole derivative that has been widely used in treatment of worm infestations in both humans and animals. As an anthelmintic, it probably works by targeting the nematode nicotinergic acetyl- choline receptor. In the market, levamisole hydrochloride tablets are available in the form of tablets. Geriatric and paediatric patients find it difficult to swallow these tablets. So in order to avoid this problem, an attempt has been made to formulate orodispersible tablets of Levamisole Hydrochloride. Theobjective of the study was to evaluate the performance of three different classes of superdisintegrants which are crospovidone (CP), sodium starch glycolate (SSG), sodium alginate (SA) in promoting disintegration and dissolution of Levamisole Hydrochloride orodispersible tablets. By using concentrations of 5%, 10% & 15% of selected superdisintegrants, orodispersible tablet was prepared by direct compression method. The tablets prepared were evaluated for various parameters like hardness, friability, disintegration time and wetting time. All the parameters were found to be within limit. The best results are shown in L3 formulation containing 15 % crosspovidone. In comparison of in vitro drug dissolution studies for all developed formulations, L3 formulation releases 98.93% of drug at the end of 10 min and disintegration time was 28.6±1.22. On the basis of the results, the formulation containing 15% crospovidone was considered as ideal among all other formulations used for the development of levamisole HCl tablets.
Cite this article:
Sampada V. Kadam, Nilima U. Rane, Chandrakant S. Magdum. Formulation and Evaluation of Orodispersible Tablets of Levamisole Hydrochloride. Asian J. Pharm. Tech. 2019; 9(2):63-68. doi: 10.5958/2231-5713.2019.00011.4
Sampada V. Kadam, Nilima U. Rane, Chandrakant S. Magdum. Formulation and Evaluation of Orodispersible Tablets of Levamisole Hydrochloride. Asian J. Pharm. Tech. 2019; 9(2):63-68. doi: 10.5958/2231-5713.2019.00011.4 Available on: https://ajptonline.com/AbstractView.aspx?PID=2019-9-2-1